CTCBIO INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7,940 KRW | +0.76% |
|
-3.52% | -25.79% |
| Mar. 21 | CTCBIO Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 2023 | An unknown buyer agreed to acquire an unknown minority stake in CTCBIO Inc. for KRW 20 billion. | CI |
| Sales 2022 | 165B 121M | Sales 2023 | 138B 101M | Capitalization | 256B 187M |
|---|---|---|---|---|---|
| Net income 2022 | 6.75B 4.93M | Net income 2023 | -15.59B -11.38M | EV / Sales 2022 | 1.01 x |
| Net Debt 2022 | 15.61B 11.39M | Net Debt 2023 | 10.61B 7.75M | EV / Sales 2023 | 1.93 x |
| P/E ratio 2022 |
22.3
x | P/E ratio 2023 |
-16.4
x | Employees | 233 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 51.76% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.76% | ||
| 1 week | -3.52% | ||
| Current month | -8.53% | ||
| 1 month | -8.21% | ||
| 3 months | -13.98% | ||
| 6 months | -18.48% | ||
| Current year | -25.79% |
1 week
7 710.00
8 090.00
1 month
7 710.009 440.00
Current year
7 710.0010 900.00
1 year
7 710.0015 900.00
3 years
5 930.0015 900.00
5 years
3 480.0015 900.00
10 years
3 480.0028 400.00
| Managers | Title | Age | Since |
|---|---|---|---|
Min-Ku Lee
CEO | Chief Executive Officer | - | - |
Hyun-Mok Park
PSD | President | 57 | - |
Sang-Ho Bae
AUD | Comptroller/Controller/Auditor | 78 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jun-Seok Byun
BRD | Director/Board Member | 52 | - |
Min-Ku Lee
CEO | Chief Executive Officer | - | - |
Geum-Ho Lee
BRD | Director/Board Member | 51 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-23 | 7,940 | +0.76% | 37,538 |
| 24-04-22 | 7,880 | +0.13% | 33,757 |
| 24-04-19 | 7,870 | -1.50% | 47,227 |
| 24-04-18 | 7,990 | +1.27% | 42,239 |
| 24-04-17 | 7,890 | -1.25% | 40,255 |
End-of-day quote Korea S.E., April 22, 2024
More quotes
CTCBIO Inc. is a Korea-based company engaged in the manufacture and marketing of pharmaceuticals, veterinary drugs, animal feed supplements and functional foods. It pharmaceuticals include anticancer agents, antibiotics, bone injury treatments, antiulcer agents, blood flow stimulants and others. Its veterinary drugs include vaccines, antibiotics, immune enhancers, enzymes, organic acid, avian influenza-related agents and others. Its animal feed supplements include pigments, kapok seed meal, sesame meal and others. Its functional food business includes the development and manufacture of enzymes, lactobacillus and related products mainly used in dairy products. It also involves in the development of pharmaceutical manufacturing technology and know-how. The Company distributes its products within domestic market and to overseas markets.
Sector
Pharmaceuticals
Calendar
2024-05-09
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -25.79% | 137M | |
| -24.22% | 66.5B | |
| +15.00% | 3.43B | |
| -0.14% | 3.18B | |
| +2.36% | 1.49B | |
| -14.76% | 1.37B | |
| -3.42% | 1.23B | |
| -27.49% | 1.21B | |
| -13.84% | 1.15B | |
| -1.95% | 1.02B |
- Stock Market
- Equities
- A060590 Stock
